Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor

NCT02750215 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT02750215
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02750215 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor
Lead sponsor
Massachusetts General Hospital
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2016
Completion date
May 31, 2021
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malignant non-small cell neoplasm of lung stage iv